Skip to main content
drug protocol number
CINC424D2301
drug sponsor
Novartis
drug study
Ruxolitinib (INC424) (Jakavi)
drug trial site
King Faisal Specialist Hospital and Research Center (Riyadh)
drug status
Ongoing
drug phase